AML-207: Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence
Zeidan A, Schuster M, Joris M, Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Ma W, Zeremski M, Kudla A, Chan G, Sekeres M. AML-207: Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence. Clinical Lymphoma Myeloma & Leukemia 2020, 20: s191-s192. DOI: 10.1016/s2152-2650(20)30733-3.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeAbsolute neutrophil countChronic myelomonocytic leukemiaAcute myeloid leukemiaMyelodysplastic syndromeEvaluable patientsIntensive chemotherapyMedian durationTransfusion independenceMarrow recoveryHematopoietic recoveryMyeloid leukemiaMyelomonocytic leukemiaEarly marrow recoveryEarly platelet recoveryUp-front treatmentManageable safety profileOpen-label studyRate of transfusionMain outcome measuresEarly hematopoietic recoveryCycle 1Cycle 2Dose delaysPartial remissionNeuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease
Fogh S, Boreta L, Nakamura J, Johnson D, S A, Kurz S. Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. Neuro-Oncology Practice 2020, 8: 11-17. PMID: 33664965, PMCID: PMC7906263, DOI: 10.1093/nop/npaa037.Peer-Reviewed Original ResearchResidual diseaseWorld Health Organization grade IISmall-volume residual diseaseMacroscopic residual diseaseTreated with procarbazineTreatment of oligodendrogliomasUp-front treatmentTreatment of brain tumorsBenefits of treatmentDelayed therapyMedian survivalVincristine chemotherapyGrade IIDiagnosed oligodendrogliomaMinimal toxicityEffective therapyEarly treatmentClinical trialsDelayed toxicityBrain tumorsPatientsChemoradiotherapyChemotherapyOligodendrogliomasTherapyGlasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
Zeidan A, Schuster M, Joris M, Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Ma W, Zeremski M, Kudla A, Chan G, Sekeres M. Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence. Journal Of Clinical Oncology 2020, 38: 7526-7526. DOI: 10.1200/jco.2020.38.15_suppl.7526.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaAcute myeloid leukemiaAbsolute neutrophil countMyelodysplastic syndromeEarly hematopoietic recoveryIntensive chemotherapyMedian durationTransfusion independenceMarrow recoveryHematopoietic recoveryPlatelet recoveryHigh-risk myelodysplastic syndromeEarly marrow recoveryEarly platelet recoveryManageable safety profilePhase Ib studyUp-front treatmentLow-dose cytarabineDose delaysPartial remissionRemission rateNeutrophil countOverall survivalOral inhibitorSafety profile
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply